DEAR VISITORS, THE NEW WEBSITE IS UNDER CONSTRUCTION, SO WE ASK FOR YOUR UNDERSTANDING IF YOU ENCOUNTER OUT-OF-DATE OR INCORRECT INFORMATION. FOR ALL QUESTIONS, WE ARE AT YOUR DISPOSAL BY PHONE +38131597597 or e-mail address: office@cigota.rs
Srpski
English
Русский
Remission of diabetes mellitus type 2 in obese patients
English
natasa.neskovic977@gmail.com, djenic.cigota@gmail.comHealth Center Uzice
Special Hospital for Thyroid and Metabolism Disorders Zlatibor
Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. Journal of diabetes. 2017; 9(4): 320–24.
Tangelloju S, Little BB, Esterhay RJ, Brock G, LaJoie AS. Type 2 Diabetes Mellitus (T2DM) “Remission” in Non-bariatric Patients 65 Years and Older. Front Public Health. 2019; 12(7): 82.
Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE et al. How do we define cure of diabetes? Diabetes care. 2009; 32(11): 2133–35.
Remission of diabetes mellitus type 2 in obese patients
The dapagliflozine-type 2 sodium glucose cotransporter inhibitor in the treatment of diabetes mellitus type 2
English
natasa.neskovic977@gmail.com, djenic.cigota@gmail.comHealth Center Uzice
Special Hospital for Thyroid and Metabolism Disorders Zlatibor
Đukić A, Đurđević P, Živančević-Simonović S, Jurišić V, Mijatović Lj. Opšta patološka fiziologija. Beograd; Intergraf: 2002; 400–408.
International Diabetes Federation. IDF Diabetes Atlas, 7th ed. International Diabetes Federation: Brussels, Belgium: 2015; available at: http://www.diabetesatlas.org
Stark Casagrande, S., Fradkin, J., Saydah, S., Rust, K. and Cowie, C. (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 36: 2271–2279.
The dapagliflozine-type 2 sodium glucose cotransporter inhibitor in the treatment of diabetes mellitus type 2
CASE REPORT – PATIENT REVIEW – THIRD DEGREE OBESITY, METABOLIC SYNDROME, INCREASED CARDIOVASCULAR RISK AND ELECTROLYTE DISBALANCE WITH THE DURATION OF BODY REDUCTION TREATMENT IN A SPECIAL HOSPITAL CIGOTA
English
djenic.cigota@gmail.comThe Special Hospital for Thyroid and Metabolism Disorders Zlatibor
Zhang C., Rexrode K.M., van Dam R.M., Li T.Y., Hu F.B. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation 2008,117: 1658–1667.
Carl J. Lavie, Richard V. Milani, Hector O. Ventura.Obesity and Cardiovascular Disease. JACC,May 2009, 53 (21):1925–1932.
Schneider R, Golzman B, Turkot S et al . Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005, 330: 157–160.
CASE REPORT – PATIENT REVIEW – THIRD DEGREE OBESITY, METABOLIC SYNDROME, INCREASED CARDIOVASCULAR RISK AND ELECTROLYTE DISBALANCE WITH THE DURATION OF BODY REDUCTION TREATMENT IN A SPECIAL HOSPITAL CIGOTA
THE INFLUANCE OF HYPOTHYREOSIS AND L-THYROXIN THERAPY ON METABOLIIC BONE TURNOVER
English
THE INFLUANCE OF HYPOTHYREOSIS AND L-THYROXIN THERAPY ON METABOLIIC BONE TURNOVER
PRACTICAL APPROACH DIAGNOSTICS OF OSTEOPOROSIS
English
PRACTICAL APPROACH DIAGNOSTICS OF OSTEOPOROSIS
CONTACT US